Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that its scientists have solved the high-resolution X-ray crystal structures of the GLP-1 (glucagon-like peptide 1) and glucagon receptors. Both receptors play important roles in the management of blood glucose levels and are considered to …
Tag Archives: Heptares Therapeutics
April, 2016
-
8 April
Allergan Inks $3.3 Billion Neurological Drug Deal with Heptares
DUBLIN and LONDON, April 6, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited and Heptares have entered into a definitive agreement …
December, 2015
-
2 December
Pfizer Enters GPCR-Based Therapy Deal with Heptares
TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas. Heptares will …